Test Home2021-06-07T10:17:32+02:00

The Psyence™ Group sets the global standard for natural psychedelics.

Informed by nature and guided by science, Psyence is a life science biotechnology company pioneering the use of natural psilocybin to heal psychological trauma and the diagnosable disorders that can result: anxiety, depression, PTSD, stress, grief and bereavement. We have a focus on these conditions in the context of palliative care.

We are focused on the development of psilocybin medical products for research institutions and clinics and will also manufacture regulatory-compliant over the counter psilocybin containing products. We are also developing nutraceutical products for depression, acute anxiety and sleep disorders.

Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and our diversified business has a global footprint with operations in multiple legal jurisdictions. We operate one of the first federally licensed commercial psilocybin cultivation and production facilities in the world in Southern Africa.

About Us

The Psyence™ Group sets the global standard for natural psychedelics.

Informed by nature and guided by science, Psyence is a life science biotechnology company pioneering the use of natural psilocybin to heal psychological trauma and the diagnosable disorders that can result: anxiety, depression, PTSD, stress, grief and bereavement. We have a focus on these conditions in the context of palliative care.

We are focused on the development of psilocybin medical products for research institutions and clinics and will also manufacture regulatory-compliant over the counter psilocybin containing products. We are also developing nutraceutical products for depression, acute anxiety and sleep disorders.

Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and our diversified business has a global footprint with operations in multiple legal jurisdictions. We operate one of the first federally licensed commercial psilocybin cultivation and production facilities in the world in Southern Africa.

About Us

Psyence is pioneering the use of natural psilocybin for the long-term treatment of trauma and its mental health consequences.

[layerslider id=”2″ /]

Bringing together leaders in the business of medicine and science

Our scientific and medical team, which includes experts in neurology, neuroscience, oncology and drug development, have international expertise in palliative medicine and science. Our global executive team has extensive capital market and business building experience and a track record for creating shareholder value and achieving sustainable growth.

Our Team
THerapuetics_Logo 400pxwide

We develop natural psilocybin products, medicinal formulations and treatment protocols to treat mental health disorders in a clinical environment.

Learn More
production_Logo 400pxwide

We operate one of the first federally licensed commercial psilocybin cultivation and production facilities in the world.

Learn More
Psyece Funcitonblue 400px

With experience in building disruptive brands and creating routes to market, we are focused on the development of over-the-counter proprietary nutraceutical products.

Learn More
Psyence_Logo 400pxwide

We will partner with experienced providers of retreats and clinics in legal jurisdictions to inform our medical and product development strategy.

Learn More

Our News

  • GOODMIND_FEATURE

GOODMIND Available For Sale In The United Kingdom And Europe – Exclusive Distribution Agreement Concluded With This Works.

November 29, 2022|

Psyence is pleased to announce that it has, together with its joint venture partner The Goodleaf Company (Pty) Ltd (“Goodleaf”), entered into an exclusive distribution agreement with This Works Products Limited (“This Works”) for the distribution and sale of the joint venture’s functional mushroom brand, GOODMINDTM, in the United Kingdom and Europe.

Psyence Group Announces Strategic Private Placement

November 10, 2022|

Psyence announce that it has received subscription agreements for gross proceeds of CAD$1.22 million from a consortium led by Brandon Kerzner, a member of the globally recognised Kerzner family. Brandon has a focus on investing in technology and life science advancement industries.

VIEW ALL

Our Global Footprint

Our team and operations are located across Toronto, Canada; Washington DC, United States of America; Cape Town, South Africa; Kolojane, Kingdom of Lesotho; Kingston, Jamaica; London United Kingdom; Sydney, Australia and Sao Paulo, Brazil.

Contact Us

Our News

  • GOODMIND_FEATURE

GOODMIND Available For Sale In The United Kingdom And Europe – Exclusive Distribution Agreement Concluded With This Works.

November 29, 2022|

Psyence is pleased to announce that it has, together with its joint venture partner The Goodleaf Company (Pty) Ltd (“Goodleaf”), entered into an exclusive distribution agreement with This Works Products Limited (“This Works”) for the distribution and sale of the joint venture’s functional mushroom brand, GOODMINDTM, in the United Kingdom and Europe.

Psyence Group Announces Strategic Private Placement

November 10, 2022|

Psyence announce that it has received subscription agreements for gross proceeds of CAD$1.22 million from a consortium led by Brandon Kerzner, a member of the globally recognised Kerzner family. Brandon has a focus on investing in technology and life science advancement industries.

VIEW ALL

Our Global Footprint

Our team and operations are located across Toronto, Canada; Washington DC, United States of America; Cape Town, South Africa; Kolojane, Kingdom of Lesotho; Kingston, Jamaica; London United Kingdom; Sydney, Australia and Sao Paulo, Brazil.

Contact Us
Go to Top